{"id":1020442,"date":"2026-11-12T10:39:03","date_gmt":"2026-11-12T15:39:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/"},"modified":"2026-11-12T10:39:03","modified_gmt":"2026-11-12T15:39:03","slug":"olema-oncology-announces-corporate-name-change","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/","title":{"rendered":"Olema Oncology Announces Corporate Name Change"},"content":{"rendered":"
\n

SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Olema Oncology, Inc.<\/a> (formerly Olema Pharmaceuticals, Inc.) (\u201cOlema\u201d or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, announced that, effective today, it has changed its corporate name from \u201cOlema Pharmaceuticals, Inc.\u201d to \u201cOlema Oncology, Inc.\u201d pursuant to the Company\u2019s Eighth Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware.<\/p>\n

The Company\u2019s common stock will continue to be listed and trade on the Nasdaq Global Select Market under the ticker symbol \u201cOLMA.\u201d Pursuant to Delaware law, no action was required by stockholders of the Company to effect the name change. Stock certificates reflecting the prior corporate name will continue to be valid.<\/p>\n

\n About Olema Oncology<\/strong>
\n
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit\u00a0www.olema.com<\/a>.<\/p>\n

\n Media and Investor Relations Contact<\/strong>
\n
Courtney O\u2019Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (\u201cOlema\u201d or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, announced that, effective today, it has changed its corporate name from \u201cOlema Pharmaceuticals, Inc.\u201d to \u201cOlema Oncology, Inc.\u201d pursuant to the Company\u2019s Eighth Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware. The Company\u2019s common stock will continue to be listed and trade on the Nasdaq Global Select Market under the ticker symbol \u201cOLMA.\u201d Pursuant to Delaware law, no action was required by stockholders of the Company to effect the name change. Stock certificates reflecting … <\/p>\n

Continue reading “Olema Oncology Announces Corporate Name Change”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1020442","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOlema Oncology Announces Corporate Name Change - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olema Oncology Announces Corporate Name Change - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (\u201cOlema\u201d or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, announced that, effective today, it has changed its corporate name from \u201cOlema Pharmaceuticals, Inc.\u201d to \u201cOlema Oncology, Inc.\u201d pursuant to the Company\u2019s Eighth Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware. The Company\u2019s common stock will continue to be listed and trade on the Nasdaq Global Select Market under the ticker symbol \u201cOLMA.\u201d Pursuant to Delaware law, no action was required by stockholders of the Company to effect the name change. Stock certificates reflecting … Continue reading "Olema Oncology Announces Corporate Name Change"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-12T15:39:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTc4NCM3OTYwOTY4IzIyMDM1MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Olema Oncology Announces Corporate Name Change\",\"datePublished\":\"2026-11-12T15:39:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/\"},\"wordCount\":268,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTc4NCM3OTYwOTY4IzIyMDM1MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/\",\"name\":\"Olema Oncology Announces Corporate Name Change - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTc4NCM3OTYwOTY4IzIyMDM1MTU=\",\"datePublished\":\"2026-11-12T15:39:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTc4NCM3OTYwOTY4IzIyMDM1MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTc4NCM3OTYwOTY4IzIyMDM1MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-corporate-name-change\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olema Oncology Announces Corporate Name Change\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Olema Oncology Announces Corporate Name Change - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/","og_locale":"en_US","og_type":"article","og_title":"Olema Oncology Announces Corporate Name Change - Market Newsdesk","og_description":"SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (\u201cOlema\u201d or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, announced that, effective today, it has changed its corporate name from \u201cOlema Pharmaceuticals, Inc.\u201d to \u201cOlema Oncology, Inc.\u201d pursuant to the Company\u2019s Eighth Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware. The Company\u2019s common stock will continue to be listed and trade on the Nasdaq Global Select Market under the ticker symbol \u201cOLMA.\u201d Pursuant to Delaware law, no action was required by stockholders of the Company to effect the name change. Stock certificates reflecting … Continue reading \"Olema Oncology Announces Corporate Name Change\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-12T15:39:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTc4NCM3OTYwOTY4IzIyMDM1MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Olema Oncology Announces Corporate Name Change","datePublished":"2026-11-12T15:39:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/"},"wordCount":268,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTc4NCM3OTYwOTY4IzIyMDM1MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/","name":"Olema Oncology Announces Corporate Name Change - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTc4NCM3OTYwOTY4IzIyMDM1MTU=","datePublished":"2026-11-12T15:39:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTc4NCM3OTYwOTY4IzIyMDM1MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTc4NCM3OTYwOTY4IzIyMDM1MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-corporate-name-change\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Olema Oncology Announces Corporate Name Change"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1020442"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020442\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1020442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1020442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1020442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}